固本咳喘制剂治疗慢性气道疾病效果的meta分析

Meta-Analysis of Clinical Efficacy of Gubenkechuan Decoction in the Treatment of Chronic Airway Diseases

目的 系统评价固本咳喘制剂对慢性气道疾病患者的治疗效果。方法 利用计算机系统从中国知网、万方期刊数据库、中国生物医学文献数据库、维普中文期刊数据库、PubMed、Embase、Cochrane Library等数据库中搜索关于固本咳喘制剂治疗慢性气道疾病的临床研究,采用Cochrane风险评价对纳入研究进行质量评价,然后用RevMan 5.4软件对临床疗效指标进行meta分析。结果 共纳入15项随机对照试验,1 516例患者。meta分析结果显示:与对照组相比,使用固本咳喘制剂治疗可提高慢性气道疾病治疗总有效率(P<0.01),在疾病亚组分析中结果保持一致。与对照组相比,使用固本咳喘制剂治疗可改善慢性气道疾病患者肺功能相关指标,并降低肿瘤坏死因子-α水平(P<0.01)。所纳入的研究均未报道严重不良反应。结论 固本咳喘制剂可以提高慢性气道疾病患者的治疗有效率,改善肺功能指标,降低血清炎症因子水平,且安全性良好。

Objective To systematically evaluate the therapeutic efficacy of Gubenkechuan on patients with chronic airway diseases.Methods The computer system was used to search for clinical studies on the treatment of chronic airway diseases with Gubenkechuan from the CNKI,WanFang,Chinese biomedical literature database,Vip database,PubMed,Embase and Cochrane Library.The Cochrane risk assessment was used to evaluate the quality of the included studies,and then meta-analysis of the clinical efficacy indicators was performed using RevMan 5.4 software.Results A total of 15 randomized controlled trials with 1516 patients were included.Meta-analysis showed that treatment with Gubenkechuan increased the overall efficacy of treatment in patients with chronic airway diseases compared to the control group(P<0.01),and the results in the subgroups were consistent with those in patients with chronic airway diseases.Compared to the control group,the treatment with Gubenkechuan also improved lung function indexes,and reduced tumor necrosis factor-αlevel in patients with chronic airway diseases(P<0.01).No serious adverse effects were reported in any of the included studies.Conclusion Gubenkechuan could increase treatment efficiency,improve lung function indexes,and reduce serum inflammatory factor levels in patients with chronic airway diseases,and has a good safety profile.